Amneal Pharmaceuticals, Inc. - 8-K Filing
Amneal Pharmaceuticals reports Q2 net revenue of $796M with adjusted EBITDA of $206M and raises full-year guidance (Items: 2.02 of this report, 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section)
Tickers: $AMRX